Professional Documents
Culture Documents
Biocon Case Summary
Biocon Case Summary
Start of Biocon:
- Incorporated in Nov. 1978. Kiran had 70% and Auchincloss 30%.
- First BioTech company in India.
- Financed by Canara Bank thanks to personal contacts.
- Hiring staff and finding offices was very hard.
- Initial operations: extract enzymes for the UK office.
Growth of Biocon:
- 1st Phase:
o 1984, beginning of R&D efforts in other enzyme technologies.
o In 3 years, became a successful producer of sophisticated Koji enzymes.
o 1989: Unilever acquires BioCon UK and 30% of BioCon India.
o Kiran refused to sell her part in Biocon India.
- 2nd Phase:
o Biocon starts contract R&D (outsourcing) for US and UE firms.
o Biocon becomes independent entity: Kiran buys the remaining 30%
- 3rd Phase:
o Expansion into the Statins business is a success: 78% of revenues in 2000.
o Expansion into the clinical studies business is promising.
o Milestone in 2001: FDA approval in the US.
- 4rd Phase:
o In 25 years, evolved from enzymes producer to major Pharma company.
o 2004: 1ST biotech cie in Asia and #16 in the world by revenues.
o Successful IPO in 2004.
o All growth metrics are spectacular (sales, net profits…)
Characteristics of Kiran:
- CSR initiatives:
o Polio camps for children and Hepatitis B.
o Biocon foundation: affordable health services for the poor.
o Health services for rural families.
o Primary education for the poor and school equipment.
o Improve quality of life in Bangalore (garbage, clean water, roads)